Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02628574 |
Recruitment Status :
Completed
First Posted : December 11, 2015
Last Update Posted : October 26, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study will be conducted in 5 parts (Parts A, B, C, D and E).
Monotherapy Treatment:
Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A. Cycle 1 data from each cohort will be evaluated for safety and dose-limiting toxicities (DLTs) prior to dose escalation. Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a patient is enrolled and cohorts will be dosed consecutively by ascending dose. Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified, an expanded cohort will be enrolled (Part B).
Combination Treatment:
Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Subjects will receive TRX518 in combination with gemcitabine (Part C), pembrolizumab (Part D), or nivolumab (Part E). Dose escalation will be performed for each part (Part Cesc, Part Desc, Part Eesc) and Cycle 1 data from each cohort will be evaluated for safety and dose-limiting toxicities (DLTs) prior to dose escalation. Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a patient is enrolled and cohorts will be dosed consecutively by ascending dose. Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified, an expanded cohort will be enrolled (Part Cexp, Part Dexp, Part Eexp).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumors | Drug: TRX518 monotherapy Drug: TRX518 with gemcitabine Drug: TRX518 with pembrolizumab Drug: TRX518 with nivolumab | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 109 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors |
Actual Study Start Date : | January 2016 |
Actual Primary Completion Date : | July 14, 2020 |
Actual Study Completion Date : | July 14, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: TRX518 monotherapy (Parts A and B)
Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
|
Drug: TRX518 monotherapy
comparison of different (ascending) doses of TRX518 monotherapy |
Experimental: TRX518 with gemcitabine (Part C)
Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
|
Drug: TRX518 with gemcitabine
comparison of different (ascending) doses of TRX518 in combination with gemcitabine |
Experimental: TRX518 with pembrolizumab (Part D
Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
|
Drug: TRX518 with pembrolizumab
comparison of different (ascending) doses of TRX518 in combination with pembrolizumab |
Experimental: TRX518 with nivolumab (Part E)
Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
|
Drug: TRX518 with nivolumab
comparison of different (ascending) doses of TRX518 in combination with nivolumab |
- Adverse events [ Time Frame: through 30 days post last dose ]Any adverse change in health or side effect from the initiation of the study drug dose TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab through completion or premature withdrawal
- TRX518 peak concentration (Cmax) [ Time Frame: various timepoints through 1 week post dose ]Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
- Time to peak concentration (Tmax) [ Time Frame: various timepoints through 1 week post dose ]Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
- Area under the curve (AUC) [ Time Frame: various timepoints through 1 week post dose ]Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
- RECIST assessment for evidence of antitumor activity [ Time Frame: up to 1 year ]RECIST assessment to determine effects of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab on solid tumors.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Advanced Solid Malignancies: Histologically documented metastatic or locally advanced, incurable solid malignancy (Parts A and B); histologically documented metastatic or locally advanced, incurable solid malignancy for which gemcitabine is clinically appropriate (e.g., non-small cell lung, breast, ovarian, pancreatic, and renal cancer); histologically documented metastatic or locally advanced, incurable solid malignancy for which pembrolizumab (Part D) or nivolumab (Part E) is approved. NOTE: Parts D and E only: Subject has either (1) received treatment with pembrolizumab or nivolumab for ≥4 months with a best response of stable disease and plans to continue treatment with either pembrolizumab or nivolumab in accordance with package insert; or (2) is not currently taking, but is eligible for treatment with, pembrolizumab or nivolumab in accordance with the approved indications for each as referenced in the package insert.
- Expected survival of at least 12 weeks after dosing.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Evidence of adequate organ function by standard laboratory tests.
- All female subjects of child bearing age must be either surgically sterile, postmenopausal for at least 1 year, or using an acceptable method of contraception. Adequate contraception for both male and female subjects must be used from the beginning of the screening period until at least 8 weeks after the last dose of study drug.
Exclusion Criteria:
- Hematologic malignancies or multiple myeloma.
- Known, clinically important cardiac or respiratory disease
- Any concomitant serious physical illness other than cancer (e.g., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing. No history of autoimmune disease.
- Active, uncontrolled infections within 7 days of study entry requiring systemic therapy.
- Evidence of progression of central nervous system (CNS) metastases or symptomatic CNS metastases within 30 days prior to dosing.
- History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment. (Parts C, D and E only).
- Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis (Parts D and E only).
- Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment (Parts D and E only).
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis (Parts D and E only).
- History of interstitial lung disease (Parts D and E only).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02628574
United States, Illinois | |
University of Chicago | |
Chicago, Illinois, United States, 60637 | |
United States, New Mexico | |
University of New Mexico Comprehensive Cancer Center | |
Albuquerque, New Mexico, United States, 87131 | |
United States, Ohio | |
University Hospitals | |
Cleveland, Ohio, United States, 44106 | |
Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 | |
United States, Pennsylvania | |
University of Pittsburgh Medical Center | |
Pittsburgh, Pennsylvania, United States, 15232 | |
United States, Tennessee | |
Tennessee Oncology | |
Nashville, Tennessee, United States, 37205 |
Study Chair: | Cyndi Sirard, MD | Leap Therapeutics, Inc. |
Responsible Party: | Leap Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT02628574 |
Other Study ID Numbers: |
TRX518-003 |
First Posted: | December 11, 2015 Key Record Dates |
Last Update Posted: | October 26, 2020 |
Last Verified: | October 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Metastatic Stage III or IV recurrent refractory solid tumors |
Gemcitabine Pembrolizumab Nivolumab Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents, Immunological |